Immunoglobulin E specific for Beta vulgaris allergen 1 and Beta vulgaris allergen 2 (sIgE (Beta v 1/Beta v 2))

Immunoglobulin E (IgE) antibodies specific for Beta v 1 and Beta v 2 epitopes are the primary immunological mediators of allergic sensitization to sugar beet (Beta vulgaris) pollen (Bardina et al., 1993, PubMed: 8331172). Beta v 1 is a pectate lyase and serves as the major allergen, while Beta v 2 is a profilin that often acts as a minor allergen but contributes significantly to cross-reactivity with other plant-derived profilins (Achatz et al., 1995, PubMed: 7594551). These specific IgE molecules function by binding to the allergen and subsequently anchoring to high-affinity FcεRI receptors on the surface of mast cells and basophils (Galli et al., 2012, PubMed: 22448595). Upon subsequent exposure to Beta vulgaris pollen, the cross-linking of these IgE-receptor complexes triggers the rapid release of inflammatory mediators, leading to symptoms of allergic rhinitis and conjunctivitis. Therapeutic strategies targeting these antibodies include the use of anti-IgE monoclonal antibodies like omalizumab, which non-specifically neutralize circulating IgE and downregulate receptor expression (Platts-Mills, 2001, PubMed: 11765751). Additionally, allergen-specific immunotherapy (AIT) aims to modify the immune response by inducing the production of IgG4 blocking antibodies that compete with IgE for allergen binding sites (Akdis & Akdis, 2014, PubMed: 24942082). Monitoring the levels of these specific IgE antibodies is crucial for diagnosing sugar beet allergy and assessing the efficacy of desensitization treatments.

Other names

Anti-Beta v 1 IgEAnti-Beta v 2 IgESugar beet pollen specific IgEIgE anti-Beta v 1IgE anti-Beta v 2Beta v 1 specific IgEBeta v 2 specific IgE

The primary mechanism involves the neutralization of circulating IgE antibodies to prevent their binding to the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade (Platts-Mills, 2001, PubMed: 11765751). In the context of immunotherapy, the goal is to shift the immune profile from a Th2-mediated IgE response to a Th1/Treg-mediated response, characterized by the induction of allergen-specific IgG4 antibodies that intercept the allergen before it can interact with IgE (Akdis & Akdis, 2014, PubMed: 24942082).